new-recommended-broker-banner new-recommended-broker-banner

Here’s Why Arrowhead Pharma (ARWR) Stoch Has Surged Over 45%…

Updated: 22 Mar 2021

Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock has climbed over 45% higher after the company announced positive interim results from its Phase 2 study of ARO-AAT in treating a rare genetic liver disease.

Arrowhead said that the therapeutic, which is being used in the study to treat a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD), showed clear evidence of a meaningful effect leading to improvements in patients.

“The improvements in additional clinically meaningful biomarkers, including reductions in Z-AAT polymer, improvements in FibroScan values, and decreases in ALT and GGT, were more substantial than we expected,” said Javier San Martin, MD, chief medical officer at Arrowhead.

new-recommended-broker-banner

Arrowhead shares…

Arrowhead ($ARWR)/Source: TradingView

The news resulted in a leap in Arrowhead’s share price. It closed Wednesday’s trading session at $33.80 and is currently trading at $49.22 per share, up over 45%.

PEOPLE WHO READ THIS ALSO VIEWED:

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .